Coverage, Billing, and Financial Assistance
For Foundation Medicine Patients

Insurance Coverage Information

- All Foundation Medicine tests are covered by Original Medicare and Medicare Advantage for qualifying patients. Qualifying patients with Original Medicare have no out-of-pocket costs for Foundation Medicine comprehensive genomic profiling tests. Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation Medicine’s testing services. FoundationOne®Heme and FoundationOne®Liquid CDx tests have limited commercial health plan coverage at this time.

Billing Information

- Foundation Medicine will make every attempt to support insurance coverage and payment for testing. If your insurance company denies coverage for a Foundation Medicine test, with your consent, Foundation Medicine will work to obtain coverage and pursue appeals.
- Foundation Medicine only bills patients after following the entire claims process. Your out-of-pocket cost will depend on your insurance plan and may include deductibles, co-insurances, copays, or non-covered charges.
- Foundation Medicine will attempt to reach out to any patient who owes more than $500.

Financial Assistance Program

Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing. Financial assistance is based on need and can be applied for at any point during the testing process.*

*Foundation Medicine’s Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.
Pricing for Foundation Medicine’s Tests

<table>
<thead>
<tr>
<th>Test Details</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOUNDATION ONE® CDx</td>
<td>$5,800.00</td>
</tr>
<tr>
<td>FOUNDATION ONE® LIQUID CDx</td>
<td></td>
</tr>
<tr>
<td>FOUNDATION ONE® HEME</td>
<td></td>
</tr>
<tr>
<td>PD-L1 (Immunohistochemistry)</td>
<td>$250.00</td>
</tr>
</tbody>
</table>

Questions

The Foundation Medicine team is here to help. If you have an Explanation of Benefits (EOB) or bill in hand and have any questions, please contact our billing department.

Call: 877.246.9204
Email: foundationmedicine@mylabbill.com
Fax: 440.528.6010

References

1. Data on File, Foundation Medicine, Inc., 2020. Based on settled claims from 1/1/19 to 3/31/20 for all tests offered by Foundation Medicine and reported during that time before considering any financial assistance. 61% of commercially insured and 90% of Medicare and Medicare Advantage patients paid $0 for Foundation Medicine testing.
2. Data on File, Foundation Medicine, Inc., 2020. Based on settled claims from 1/1/19 to 3/31/20 for all tests offered by Foundation Medicine and reported during that time before considering any financial assistance. 65% of commercially insured and 97% of Medicare and Medicare Advantage patients had or qualified for a payment of $100 or less for Foundation Medicine testing. The percentages provided are for cases reported between 01/01/2019-12/31/2019.
3. Medicare administered by federal government.
4. Medicare administered by private insurers.
5. For FoundationOne®CDx and FoundationOne®Liquid CDx, see “Decision for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced cancer – CAG-00450R,” (See Appendix B)
6. For FoundationOne®Heme, see the “Local Coverage Determination (LCD): MolDX: NEXT-GENERATION Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047)

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if available. For the complete label, including companion diagnostic indications and important risk information, please visit http://www.F1CDxLabel.com and http://www.F1LCDxLabel.com.

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at http://foundationoneheme.com/.